SLATE

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Tuesday, March 5, 2024
Human services, Research, Gritstone bio, NCI, Messenger, Immunotherapy, FDA, Food, SLATE, GMP, National Cancer Institute, Vaccine, Administration, Autumn, COVID-19, Collaboration, Patient, Clinical trial, Infection, IND, Development, Workforce, HIV, Pharmaceutical industry

EMERYVILLE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Positive signal in this metastatic context would likely unlock enormous opportunity in both adjuvant and metastatic solid tumors.
  • Gritstone met its enrollment target of 100 patients randomized in August 2023.
  • Cash, cash equivalents, marketable securities and restricted cash were $86.9 million as of December 31, 2023, compared to $185.2 million as of December 31, 2022.
  • Research and development expenses were $127.2 million for the year ended December 31, 2023 compared to $111.4 million for the year ended December 31, 2022.

Weber ‘Brings the Heat’ With Series of Industry-First, Intelligently Designed Innovations to Make Cooking Outdoors More Enjoyable and Delicious Than Ever

Retrieved on: 
Tuesday, January 9, 2024
Home Goods, Food Tech, Specialty, Consumer Electronics, Technology, Apps, Applications, Food, Beverage, Retail, CONNECT, Camping, Heart, GENESIS, Barbecue, Geography, Collection, Temperature, Cooking, Griddle, SLATE, Stainless steel, SPIRIT, Baking

"Our company's latest products are our most advanced and innovative yet," said Mike Jacobs, Chief Operating Officer of Weber.

Key Points: 
  • "Our company's latest products are our most advanced and innovative yet," said Mike Jacobs, Chief Operating Officer of Weber.
  • The all-new 2024 SUMMIT smart gas grill is the most technologically advanced, versatile, premium offering in the Company’s gas portfolio.
  • Weber designed it exclusively for outdoor cooks who seek a high-performing culinary showstopper for their outdoor space.
  • For the ultimate smart and easy-to-manage grilling experience, SUMMIT gas grill owners can also rely on the WEBER CONNECT App.

Weber ‘Brings the Heat’ With Series of Industry-First, Intelligently Designed Innovations to Make Cooking Outdoors More Enjoyable and Delicious Than Ever

Retrieved on: 
Tuesday, January 9, 2024
Retail, Home Goods, Specialty, Food, Beverage, CONNECT, Camping, LCD, Heart, Geography, Collection, Temperature, Cooking, Smoking, Multimedia, Griddle, SLATE, Stainless steel, Baking

"Our company's latest products are our most advanced and innovative yet," said Mike Jacobs, Chief Operating Officer of Weber.

Key Points: 
  • "Our company's latest products are our most advanced and innovative yet," said Mike Jacobs, Chief Operating Officer of Weber.
  • The all-new 2024 SUMMIT smart gas grill is the most technologically advanced, versatile, premium offering in the Company’s gas portfolio.
  • Weber designed it exclusively for outdoor cooks who seek a high-performing culinary showstopper for their outdoor space.
  • For the ultimate smart and easy-to-manage grilling experience, SUMMIT gas grill cooks can also rely on the WEBER CONNECT App.

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, November 8, 2023
PCV, SLATE, CORAL, FDA, Biomedical Advanced Research and Development Authority, Research, IND, Gritstone bio, NCI, Food, Health, Infection, Vaccine, Human services, National Institutes of Health Clinical Center, Administration for Strategic Preparedness and Response, HIV, Gates, BARDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, United States Department of Health and Human Services, Administration, Development, Gilead, NAB, Clinical trial, COVID-19, National Cancer Institute, Messenger, Collaboration, Immunotherapy, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Cancer, CEPI, Chemistry, Patient, Pharmaceutical industry, Gritstone, LNP

EMERYVILLE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the third quarter ended September 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • In oncology, preliminary findings from the randomized Phase 2/3 study of our personalized cancer vaccine, GRANITE, in MSS-CRC are rapidly approaching.
  • The scientific bedrock of GRANITE extends to SLATE, where our collaboration with Steven A. Rosenberg and the NCI is now advancing.
  • Gritstone met its enrollment target of 100 patients randomized in August 2023.
  • An IND to run a Phase 1 study was cleared by the U.S. Food and Drug Administration (FDA) in October 2023.

CHERRY Extends Keyboard and Mouse Product Line with Exciting New Options for Both Mobile and Office Working

Retrieved on: 
Tuesday, September 19, 2023
MSRP, Light-emitting diode, MINI, Workplace, Lethargy, USB, FN, BT, Tablet, Amazon, F1, UV, Bluetooth, SLATE, Longevity, Peter Hancock (professor), Software, Electric motor, Video game

CHERRY KW 7100 MINI BT: Minimalist multi-device keyboard with focus on flexibility and mobile working.

Key Points: 
  • CHERRY KW 7100 MINI BT: Minimalist multi-device keyboard with focus on flexibility and mobile working.
  • The in-house CHERRY SX scissor mechanism guarantees maximum precision and ergonomics: the slightly concave-shaped keys enable smooth and quiet typing.
  • Flexibility is an important key point of modern workplaces relying on shared desk models, coworking spaces and mobile working.
  • The CHERRY KW 7100 MINI BT is available in three colors - SLATE BLUE, AGAVE GREEN, and CHERRY BLOSSOM at an MSRP of $59.99.

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, August 9, 2023
KRAS, Chemistry, Congress, Lance, Patient, SLATE, Collaboration, Infection, Maintenance, Monitoring, Vaccination, Gritstone bio, Immunity, Research, Melinda French Gates, Gilead, ECCMID, CORAL, NCI, Vaccine, DNA, AACR, COVID-19, African, Cancer, NAB, Immunotherapy, Messenger, Government, Friends, National Cancer Institute, Bill & Melinda Gates Foundation, European, NIAID, Partnership, Circulating tumor DNA, Drug development, CRC, HIV, CMC, Clinical trial, Nature Communications, PCV, Cryptocurrency, Pharmaceutical industry, Neoplasm, Gritstone

EMERYVILLE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Molecular response, or reduction in ctDNA, is the primary efficacy endpoint for the Phase 2 portion of the GRANITE trial.
  • Gritstone delivered multiple presentations detailing advances in neoantigen prediction capabilities and cancer vaccine programs at the 2023 American Association for Cancer Research (AACR 2023, in April 2023).
  • Gritstone expects to initiate a randomized Phase 2 clinical trial within SLATE (“off-the-shelf” neoantigen vaccine program) in 2024.
  • Gritstone expects to share additional data from the CORAL-CEPI and CORAL-BOOST studies in Fall 2023.

Chenega Analytic Business Solutions Brings 100 Employment Opportunities to St. Louis

Retrieved on: 
Wednesday, July 19, 2023
Partnership, Employment, College of the Holy Cross, National Personnel Records Center, Organization of the National Archives and Records Administration, Veteran, ID, Reproduction, National archives, CABS, GED, SLATE, Federation, NARA, Nursing, St. Louis

ST. LOUIS, July 19, 2023 /PRNewswire/ -- Chenega Analytic Business Solutions (CABS) is proud to announce its new contract with the National Archives and Records Administration (NARA) National Personnel Records Center in St. Louis, MO.

Key Points: 
  • ST. LOUIS, July 19, 2023 /PRNewswire/ -- Chenega Analytic Business Solutions (CABS) is proud to announce its new contract with the National Archives and Records Administration (NARA) National Personnel Records Center in St. Louis, MO.
  • With this award comes the opportunity to employ over 100 people in the St. Louis region, adding to the already exemplary workforce that CABS parent company, Chenega MIOS, a 2023 St. Louis Post Dispatch Top Workplace, has in the area.
  • Continuing our partnership with SLATE, CABS will be on site on July 26th at the St Louis County Library Natural Bridge Branch to support their Employment and Resource Navigator Event.
  • For more information on Chenega Analytic Business Solutions or its parent company Chenega MIOS, we encourage you to check out the following resources.

Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
KRAS, SIV, Coalition, National Institute of Allergy and Infectious Diseases, Survival, RECIST, Congress, Lance, Patient, SLATE, Collaboration, Infection, Vaccination, Gritstone bio, National Cancer Institute, Research, Melinda French Gates, Lung cancer, ECCMID, Bill, CORAL, Conference, Vaccine, DNA, Gilead Sciences, Simian immunodeficiency virus, ESMO, CEPI, African, NSCLC, NAB, Immunotherapy, Messenger, CROI, Bill & Melinda Gates Foundation, European, NIAID, Epidemic, Circulating tumor DNA, CRC, HIV, Progression-free survival, SARS-CoV-2, Clinical trial, Coalition for Epidemic Preparedness Innovations, ChAdOx1, Fungal infection, Cryptocurrency, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • We recently observed durable neutralizing antibody titers at 6 months following samRNA vaccination in over 100 vaccine-naïve subjects treated within our CORAL-CEPI trial, where interim results were presented at ECCMID 2023.
  • As of May 10, 2023, the company had randomized 71 of the initially planned 80 total patients.
  • Both datasets were presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023).
  • In February 2023, results from a preclinical study conducted in collaboration with Gilead were presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2023.

Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Vaccine, KRAS, AACR, HLA, Allele, Gritstone bio, Survival, Cancer, TCR, Patient, Ipilimumab, Accuracy and precision, Biology, Neoplasm, SLATE, Nivolumab, Gritstone

EMERYVILLE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, is delivering three presentations related to the company’s neoantigen vaccine programs and capabilities at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida. An oral presentation (minisymposium) on April 16 highlighted data from the Phase 1/2 study of GRANITE, the company’s personalized (also referred to as “individualized”) neoantigen vaccine program which is now in a randomized Phase 2/3 study for first-line microsatellite-stable colorectal cancer (MSS-CRC). The poster presentations, occurring April 17 and 18, will address the company’s proprietary neoantigen prediction capabilities (EDGE™) and “off-the-shelf” neoantigen vaccine program, SLATE.

Key Points: 
  • The poster presentations, occurring April 17 and 18, will address the company’s proprietary neoantigen prediction capabilities (EDGE™) and “off-the-shelf” neoantigen vaccine program, SLATE.
  • “Gritstone was originally founded to create best-in-class personalized and ‘off-the-shelf’ cancer vaccines through deep learning-enabled neoantigen prediction and deployment of potent vaccine platforms that drive robust T cell responses against delivered neoantigens.
  • These presentations at AACR highlight our continued progress in this endeavor,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • “Our antigen prediction platform, EDGE™, which we believe leads the field in neoantigen prediction, is being enhanced to identify class II HLA-presented neoantigens.

Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023
Cancer, AACR, Gritstone bio, Vaccine, Patient, SLATE, CD4, KRAS, Pharmaceutical industry

EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida.

Key Points: 
  • EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida.
  • The poster presentations will address the company’s proprietary neoantigen prediction capabilities (EDGE™) and “off-the-shelf" neoantigen vaccine program, SLATE.
  • The minisymposium will review results from the Phase 1/2 study of GRANITE, the company’s fully-individualized neoantigen vaccine program which is now in a randomized Phase 2/3 study for first-line microsatellite-stable colorectal cancer (MSS-CRC).
  • Abstract 2267 (Poster Presentation): HLA-DR-restricted CD4 T cell responses to KRAS G12C in healthy donors linked to bacterial mimotope: lessons for KRAS neoantigen vaccines in cancer patients